Quantcast

Latest Daunorubicin Stories

2014-04-25 09:23:29

CPX-351 treatment leads to higher chances of remission compared to standard options in AML Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation. "Acute myeloid leukemia is an aggressive blood cancer with very low...

2012-12-10 16:38:13

Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today at the 54th Annual Meeting of the American Society of Hematology (ASH). While the cancer research community has seen many significant therapeutic advances over the last decade, only recently have investigators identified how patients' individual genetic makeup influences...

2012-03-15 17:18:00

University Hospitals Case Medical Center cancer researcher helps advance 'individualized' patient care with the find New research published in the March 15 issue of the New England Journal of Medicine (embargoed 5 pm ET March 14) identifies gene mutations associated with improved overall survival with higher doses of chemotherapy for patients with acute myeloid leukemia (AML). According to one of the authors, Hillard M. Lazarus, MD, Director of Novel Cell Therapy at Seidman Cancer...

2011-12-19 10:24:54

Study indicates that drug toxicity may be related to genetic factors Will a drug used to treat childhood acute lymphoblastic leukemia and other pediatric cancers cause heart problems later in life? UB associate professor of pharmaceutical sciences, Javier G. Blanco, PhD, who sees his work as a bridge between research and clinical practice, has focused recent efforts on trying to answer this question. Blanco and colleagues' recent study in the Journal of Clinical Oncology looked for...

2011-06-27 11:45:00

NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ -- Recent findings published in the scientific journal Leukemia Research (http://www.sciencedirect.com/science/article/pii/S0145212611002505), showed that when combined with standard anti-leukemia agents, the biological activity of Leukothera(TM), a drug candidate under development by Actinobac Biomed, Inc., showed synergistic anti-leukemia effects. The outcome of these in vitro experiments demonstrated that combining Leukothera(TM) with...

2010-11-29 07:00:00

PRINCETON, N.J., Nov. 29, 2010 /PRNewswire/ -- Celator Pharmaceuticals today announced that three abstracts on its lead program, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, will be presented at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, including a podium presentation on results from a randomized, Phase 2 trial in elderly patients with newly diagnosed acute myeloid leukemia (AML) that compared treatment with CPX-351 to conventional cytarabine...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related